Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Total Inventories : $16.81 Mil (As of Jun. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Clarus Therapeutics Holdings Total Inventories?

Clarus Therapeutics Holdings's total inventories for the quarter that ended in Jun. 2022 was $16.81 Mil. Clarus Therapeutics Holdings's average total inventories from the quarter that ended in Mar. 2022 to the quarter that ended in Jun. 2022 was $15.87 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Clarus Therapeutics Holdings's Net-Net Working Capital per share for the quarter that ended in Jun. 2022 was $-0.54.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Clarus Therapeutics Holdings's Days Inventory for the three months ended in Jun. 2022 was 1,248.20.

Inventory Turnover measures how fast the company turns over its inventory within a year. Clarus Therapeutics Holdings's Inventory Turnover for the quarter that ended in Jun. 2022 was 0.07.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Clarus Therapeutics Holdings's Inventory-to-Revenue for the quarter that ended in Jun. 2022 was 3.92.

Clarus Therapeutics Holdings Total Inventories Historical Data

The historical data trend for Clarus Therapeutics Holdings's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarus Therapeutics Holdings Total Inventories Chart

Clarus Therapeutics Holdings Annual Data

Trend

Dec20

Dec21

Total Inventories

5.86

14.21

Clarus Therapeutics Holdings Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Total Inventories	Get a 7-Day Free Trial			-	12.48	14.21	14.93	16.81

Clarus Therapeutics Holdings Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Clarus Therapeutics Holdings (OTCPK:CRXTQ) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Clarus Therapeutics Holdings's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2022 is

	Net-Net Working Capital Per Share (Q: Jun. 2022 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(19.173	+	0.75 * 8.705	+	0.5 * 16.805	-	62.003
-	0	-	0)	/	52.0207
=	-0.54

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Clarus Therapeutics Holdings's Days Inventory for the three months ended in Jun. 2022 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Jun. 2022 )	/	Cost of Goods Sold (Q: Jun. 2022 )	*	Days in Period
	=	15.8675	/	1.16	*	365 / 4
	=	1,248.20

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Clarus Therapeutics Holdings's Inventory Turnover for the quarter that ended in Jun. 2022 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Jun. 2022 )	/	Average Total Inventories (Q: Jun. 2022 )
	=	1.16	/	15.8675
	=	0.07

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Clarus Therapeutics Holdings's Inventory to Revenue for the quarter that ended in Jun. 2022 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Jun. 2022 )	/	Revenue (Q: Jun. 2022 )
	=	15.8675	/	4.05
	=	3.92

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Clarus Therapeutics Holdings Total Inventories Related Terms

Thank you for viewing the detailed overview of Clarus Therapeutics Holdings's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Clarus Therapeutics Holdings Inc (OTCPK:CRXTQ) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

555 Skokie Boulevard, Suite 340, Northbrook, IL, USA, 60062

Website

https://www.clarustherapeutics.com

Clarus Therapeutics Holdings Inc is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is focused on focused on the commercialization of JATENZO (testosterone undecanoate), the first and only oral testosterone replacement, or testosterone replacement therapy, and JATENZO is the sole source of company's revenue.

Executives

Thomas Mcnerney & Partners Lp	10 percent owner	45 S. 7TH ST., SUITE 3060, MINNEAPOLIS MN 55402
Kimberly M Murphy	director	101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Elizabeth Cermak	director	1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517
Prygocki Mark A Sr	director	C/O MEDICS, 8125 N. HAYDEN RD, SCOTTSDALE AZ 85258
John Kenneth Amory	director	C/O CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662
Robert E. Dudley	director, officer: Chief Executive Officer	555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062
Joseph Hernandez	director	C/O MICROLIN BIO, INC., NEW YORK NY 10022
Richard D Peterson	officer: Chief Financial Officer	1110 WEST COMMERCIAL BOULEVARD, FORT LAUDERDALE FL 33309
Frank Jaeger	officer: Chief Commercial Officer	CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662
Steven A. Bourne	officer: Chief Administrative Officer	555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062
Ffi Fund Ltd	10 percent owner	DMS HOUSE, 20 GENESIS CLOSE, GRAND CAYMAN, GEORGE TOWN E9 KY1-1208
Thomas, Mcnerney & Partners Ii L.p.	10 percent owner	45 SOUTH 7TH STREET, SUITE 3060, Minneapolis MN 55402
Thomas, Mcnerney & Partners Ii, Llc	10 percent owner	45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Tmp Nominee Ii, Llc	10 percent owner	45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Tmp Associates Ii Lp	10 percent owner	45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402